KalVista Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:4XC1 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
05 Nov 24	Buy€10,990,800	Frazier Life Sciences Management, LP	Company	1,200,000	€9.16
28 Mar 24	Sell€13,799,192	TCG Crossover Management, LLC	Company	1,355,014	€10.18
20 Feb 24	Buy€924,289	Frazier Life Sciences Management, LP	Company	65,573	€14.10
16 Feb 24	Sell€12,207,432	TCG Crossover Management, LLC	Company	877,125	€15.06
14 Feb 24	Sell€558,132	Christopher Yea	Individual	39,886	€13.99
14 Feb 24	Sell€394,202	Edward Feener	Individual	28,171	€13.99
14 Feb 24	Sell€816,585	Thomas Crockett	Individual	58,356	€13.99
14 Feb 24	Sell€571,691	Benjamin Palleiko	Individual	40,855	€13.99
08 Feb 24	Buy€1,168,523	VR Adviser, LLC	Company	86,048	€13.69
30 Jan 24	Buy€1,176,251	VR Adviser, LLC	Company	88,099	€13.35
25 Jan 24	Buy€82,574	VR Adviser, LLC	Company	7,030	€11.75
24 Jan 24	Buy€1,139,370	VR Adviser, LLC	Company	99,129	€11.52
19 Jan 24	Buy€1,655,492	VR Adviser, LLC	Company	143,605	€11.58
16 Jan 24	Buy€306,409	VR Adviser, LLC	Company	26,246	€11.69
10 Jan 24	Buy€1,575,047	VR Adviser, LLC	Company	137,700	€11.56
04 Jan 24	Buy€657,496	VR Adviser, LLC	Company	59,369	€11.13
29 Dec 23	Buy€5,849,474	VR Adviser, LLC	Company	519,017	€11.31
12 Dec 23	Buy€2,754,410	Frazier Life Sciences Management, LP	Company	343,435	€8.84

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4XC1?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	734,838	1.44%
Hedge Funds	8,212,005	16.1%
VC/PE Firms	11,137,598	21.8%
Institutions	30,988,263	60.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.1%.

Top Shareholders

Top 25 shareholders own 106.55% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.5%	VR Adviser, LLC	6,249,731	€69.4m	0%	2.81%
11.3%	Frazier Life Sciences Management, LP	4,887,867	€54.3m	32.5%	1.85%
10%	Tang Capital Management, LLC	4,321,547	€48.0m	2.43%	3.01%
9.75%	Suvretta Capital Management, LLC	4,212,005	€46.8m	0.48%	1.42%
9.26%	Vestal Point Capital, LP	4,000,000	€44.4m	73.9%	3.04%
7.81%	Capital Research and Management Company	3,374,064	€37.5m	4.54%	no data
7.09%	BlackRock, Inc.	3,062,319	€34.0m	3.98%	no data
4.98%	The Vanguard Group, Inc.	2,150,527	€23.9m	8.03%	no data
3.68%	Tavistock Life Sciences	1,590,000	€17.6m	0%	0.97%
3.44%	Emerald Advisers, LLC	1,486,968	€16.5m	26.7%	0.29%
3.29%	Adage Capital Management, L.P.	1,419,792	€15.8m	-30.7%	0.02%
3.01%	Great Point Partners, LLC	1,299,503	€14.4m	-2.92%	4.49%
2.94%	State Street Global Advisors, Inc.	1,271,609	€14.1m	68.1%	no data
2.08%	BioImpact Capital LLC	896,915	€10.0m	1.7%	1.35%
1.92%	Geode Capital Management, LLC	830,984	€9.2m	3.07%	no data
1.67%	Dafna Capital Management, LLC	723,678	€8.0m	-10.3%	1.71%
1.41%	Woodline Partners LP	608,253	€6.8m	304%	0.05%
1.4%	Dimensional Fund Advisors LP	607,036	€6.7m	13.5%	no data
1.33%	Silverarc Capital Management, LLC	574,558	€6.4m	2.44%	1.25%
1.29%	Saturn V Capital Management LP	556,489	€6.2m	-50.7%	2.14%
1%	Schroder Investment Management Limited	431,232	€4.8m	-7.86%	no data
0.89%	Medical Strategy GmbH, Asset Management Arm	382,666	€4.2m	0%	0.21%
0.88%	Northern Trust Global Investments	379,375	€4.2m	14%	no data
0.87%	Jefferies Financial Group Inc.,Asset Management Arm	375,000	€4.2m	114%	0.17%
0.82%	First Turn Management, LLC	355,000	€3.9m	-66.5%	0.54%